GAITHERSBURG, Md. and
SHANGHAI, July 13, 2020
/PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq:
CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged
in the drug development of immunotherapies for cancer and stem cell
therapies for degenerative diseases, provided an overview and
update of clinical and pre-clinical programs currently being
researched and developed.
The Company is currently conducting the following studies:
Immuno-oncology
- Anti-BCMA CAR targeting Multiple Myeloma (MM)
- Anti-CD19/CD20 BiCAR targeting NHL
- AFP TCR-T targeting hepatocellular carcinoma (HCC)
- TIL1 (combo w/ anti-PD-1) targeting non-small cell lung cancer
(NSCLC) – Pre-clinical
Anti-BCMA CAR, Anti-CD19/CD20 BiCAR, and TCR clinical studies up
to date are conducted through IIT (investigator-initiated
trial).
Regenerative - Human Adipose Mesenchymal Progenitor Cells
(haMPC)
- ReJoin® Autologous therapy for Knee Osteoarthritis
(KOA) – Phase II
- AlloJoin® Allogenic therapy for KOA – Phase II
AlloJoin® and Re-Join® were both approved
for Phase 2 clinical trial by the Center for Drug Evaluation (CDE)
in 2019.
The presentation included an overview from CEO and CFO, Tony
(Bizuo) Liu, an update on the clinical pipelines by CSO Dr.
Yihong Yao and Head of Development
& Strategy Dr. Michael
Humphries.
"We are pleased to provide an overview of the development work
we are undertaking at CBMG. Our goal is to showcase the various
technology platforms and the current status of each of those
platforms. We are cautiously optimistic about our targets, but our
optimism has been bolstered by the preliminary outcomes of the
clinical data thus far," said Tony (Bizuo) Liu, CEO and CFO of
CBMG. Mr. Liu added "The COVID-19 pandemic has delayed
enrollment and infusion of clinical trial patients, however we
believe that we are now back to full capacity and continue to
execute our vision to deliver safe and effective drugs to patients
suffering from cancer and degenerative diseases."
A copy of the presentation and transcript will be available on
the Company website at:
https://www.cellbiomedgroup.com/investor-relations/presentations?lang=en
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. The company conducts immuno-oncology and
stem cell clinical trials in China
using products from its integrated GMP laboratory. The Company's
GMP facilities in China,
consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a "Joint Laboratory
of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy
Technology Innovation and Application Center" with Thermo Fisher
Scientific. These partnerships focus on improving manufacturing
processes for cell therapies. CBMG currently has ongoing CAR-T
Phase I clinical trials in China.
The China NMPA (formerly CFDA) approved the Company's IND
application for a Phase II trial for AlloJoin®, CBMG's
"Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee
Osteoarthritis (KOA), and has accepted the Company's IND
application for a Phase II trial for ReJoin® autologous haMPC
therapy for the treatment of KOA. The NMPA has also accepted CBMG's
dossier for an IND application for clinical trials of anti-BCMA
CAR-T. CBMG is included in the broad-market Russell 3000® Index the
small-cap Russell 2000® Index and the Loncar China BioPharma index.
To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
specific activities, and other statements that are not descriptions
of historical facts, including our statements regarding enrollment
of clinical trial patients and expectations relating to the
development, safety and efficacy of our drugs, may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include any risks
detailed from time to time in CBMG's reports filed with the
Securities and Exchange Commission, Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K,
including risks relating to the impact of the COVID-19 pandemic on
our operations, including risks associated with the evolving
COVID-19 pandemic and actions taken in response to it. Generally,
the words "believes," "anticipates," "may," "will," "should,"
"could," "expect," "plans," "intend," "estimate," "projects,"
"presents," "potential," "continue" and similar expressions or the
negative thereof or comparable terminology are intended to identify
forward-looking statements. These statements reflect our current
views with respect to future events or to our future
activities and involve known and unknown risks, uncertainties and
other factors which may cause our actual activities, actions or
achievements to be materially different from any future activities,
actions or achievements expressed or implied by the forward-looking
statements. Given these uncertainties, you should not place undue
reliance on these forward-looking statements.
Company/Investor Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-cbmg-hosts-rd-showcase-and-provides-updates-to-clinical-programs-301092132.html
SOURCE Cellular Biomedicine Group